What is Cancer Immunotherapy?
Cancer immunotherapy is one of the most transformative medical breakthroughs of the modern era, fundamentally changing how the United States approaches one of its most devastating diseases. At its core, cancer immunotherapy refers to a collection of treatments that work by harnessing, training, or amplifying the body’s own immune system to detect, attack, and destroy cancer cells — rather than relying solely on external agents like chemotherapy or radiation to kill those cells directly. In America, immunotherapy now spans several broad categories: immune checkpoint inhibitors (ICIs), CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy), cancer vaccines, cytokine therapies, monoclonal antibodies, and tumor-infiltrating lymphocyte (TIL) therapies. Each of these approaches harnesses different arms of the immune response, and together they have given oncologists an entirely new arsenal against malignancies that were once considered untreatable.
As of 2026, the United States stands at the center of the global cancer immunotherapy revolution, backed by billions of dollars in federal research funding through the National Cancer Institute (NCI) and the National Institutes of Health (NIH), alongside robust private sector investment and an unprecedented volume of active clinical trials. The American Cancer Society’s landmark Cancer Statistics 2026 report documents a historic milestone: the five-year relative survival rate for all cancers in the U.S. has now reached 70% — a figure that stood at just 49% in the mid-1970s, before the immunotherapy era began. This leap of 21 percentage points over roughly five decades reflects not incremental tinkering, but a genuine paradigm shift — one in which cancer immunotherapy is increasingly central to standard-of-care protocols across dozens of cancer types.
Interesting Cancer Immunotherapy Facts in the US 2026
| Fact | Detail |
|---|---|
| US 5-year cancer survival rate (2015–2021) | 70% — up from 49% in the mid-1970s |
| Estimated new US cancer diagnoses in 2026 | ~2.1 million Americans |
| Estimated cancer deaths in the US in 2026 | ~626,000 |
| Cancer deaths averted since 1991 (through 2023) | Approximately 4.8 million deaths averted |
| Decline in cancer death rate since 1991 | 34% overall reduction |
| Metastatic melanoma 5-year survival — pre-immunotherapy era | ~16% |
| Metastatic melanoma 5-year survival — current era | ~35% (driven by checkpoint inhibitors) |
| FDA-approved immune checkpoint inhibitors (as of early 2026) | 11 ICIs with approvals across 20+ cancer types |
| Pembrolizumab (Keytruda) FDA-approved indications | 35 distinct indications — the broadest of any single ICI |
| FDA-approved CAR-T cell therapies (as of late 2024/2025) | 6 to 7 FDA-approved CAR-T therapies |
| CAR-T remission rate in certain lymphomas | Up to 80% remission in some blood cancers |
| 5-year survival rate for NSCLC with pembrolizumab (PD-L1 ≥50%) | 23.2% vs. 15.5% with chemotherapy alone |
| 5-year overall survival — nivolumab + ipilimumab combo in advanced melanoma | 52% — compared to ~6.2-month median OS with chemotherapy |
| Pancreatic cancer 5-year survival rate (2026) | 13% — stagnant despite advances elsewhere |
| Localized lung cancer 5-year survival rate | 65% — vs. just 10% for distant-stage disease |
| Only ~18% of eligible patients received lung cancer screening | Despite screening reducing mortality by up to 24% in high-risk individuals |
| NCI FY2026 appropriation (Consolidated Appropriations Act, 2026) | $7.35 billion — an increase of $128 million over FY2025 |
| Cancer survivors living in the US (as of Jan 1, 2025) | 18.6 million — projected to exceed 22 million by 2035 |
| Full course of immunotherapy cost per patient | More than $150,000 per patient |
| Childhood leukemia 5-year survival rate — current era | 89% — up from 50% in the mid-1970s |
Source: American Cancer Society Cancer Statistics 2026; NCI Congressional Budget, Consolidated Appropriations Act 2026; ACS Cancer Treatment and Survivorship Statistics 2025; Cancer Research Institute (CRI) 2026; NBER 2026; PMC/NIH peer-reviewed publications 2025
These facts collectively paint a picture of extraordinary scientific achievement alongside persistent gaps that demand urgent attention. The jump in metastatic melanoma survival from 16% to 35% within just two decades represents the direct, measurable impact of immune checkpoint inhibitors — specifically anti-PD-1 and anti-CTLA-4 therapies — being introduced into clinical practice. The 4.8 million deaths averted since 1991 is not an abstract statistic; it represents millions of families who still have their loved ones because of a sustained, decades-long investment in cancer immunotherapy research in America. At the same time, the stagnation of pancreatic cancer survival at 13% and the fact that fewer than one in five eligible Americans receives lung cancer screening remind us that scientific breakthroughs only save lives if they reach patients who need them.
Cancer Immunotherapy Survival Statistics in the US 2026
| Cancer Type | Pre-Immunotherapy Era 5-Year Survival | Current 5-Year Survival (2026) | Key Immunotherapy Driver |
|---|---|---|---|
| All Cancers Combined | 49% (mid-1970s) | 70% (2015–2021 data) | Broad ICI + targeted therapy adoption |
| Metastatic Melanoma | ~16% | ~35% | Anti-PD-1 + anti-CTLA-4 checkpoint inhibitors |
| Advanced Melanoma (combo nivolumab + ipilimumab) | Median OS ~6.2 months (chemo) | 52% at 5 years | Dual checkpoint blockade |
| Non-Small Cell Lung Cancer (NSCLC) — PD-L1 ≥50% | ~15–16% (chemo, 5-yr) | ~23.2% | Pembrolizumab monotherapy |
| Localized Lung Cancer | Lower (often late-stage at diagnosis) | 65% | Early detection + ICI integration |
| Distant-Stage Lung Cancer | N/A | 10% | Limited immunotherapy benefit at distance |
| Kidney Cancer (overall) | ~20% (mid-1970s) | ~78% | ICI + targeted therapies (TKIs) |
| Childhood Leukemia | ~50% (mid-1970s) | ~89% | CAR-T cell therapy + targeted agents |
| Pancreatic Cancer | ~10–12% | 13% | Minimal immunotherapy impact — ongoing trials |
| Uterine Corpus Cancer | — | Rising mortality for 26 consecutive years | Unmet immunotherapy need |
Source: American Cancer Society Cancer Statistics 2026; ACS Cancer Treatment and Survivorship Statistics 2025 (PMC/NIH); Cancer Research Institute (CRI) analysis, February 2026; OncoDaily clinical trial data 2025
The survival statistics table above captures the defining story of cancer immunotherapy in America: dramatic, life-changing progress for certain cancers and near-complete stagnation for others. The leap in kidney cancer survival from 20% to 78% represents one of the most striking transformations in oncology history, driven by the combination of immune checkpoint inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs). Similarly, the milestone of 89% five-year survival in childhood leukemia — up from just 50% in the 1970s — demonstrates what happens when sustained federal research investment, including in CAR-T cell therapy, is maintained over decades. These are not marginal gains; they represent children who now grow up to live full lives.
The contrast with pancreatic cancer (13% survival, essentially unchanged) and the 26-year rise in uterine corpus cancer mortality is stark and sobering. These cancers currently lack effective immunotherapy options, largely because their tumor microenvironments are “cold” — they fail to attract the T-cells and immune activity that checkpoint inhibitors rely upon to function. Closing this gap is the defining research challenge for US cancer immunotherapy in 2026 and beyond, requiring both continued federal investment and accelerated clinical trials targeting these resistant malignancies.
FDA-Approved Cancer Immunotherapy Treatments in the US 2026
| Immunotherapy Category | Number FDA-Approved (US) | Cancer Types Covered | Notable Example |
|---|---|---|---|
| Immune Checkpoint Inhibitors (ICIs) | 11 approved ICIs | 20+ cancer types + tumor-agnostic indications | Pembrolizumab (Keytruda) — 35 indications |
| CAR-T Cell Therapies | 6–7 FDA-approved therapies | Leukemia, Lymphoma, Multiple Myeloma | Lisocabtagene maraleucel (Breyanzi), Tisagenlecleucel |
| T-Cell Engaging Bispecific Antibodies | 6 FDA-approved | Blood cancers, rare solid tumors | Multiple myeloma, certain lymphomas |
| Tumor-Infiltrating Lymphocyte (TIL) Therapy | Emerging — lifileucel approved for melanoma | Melanoma; trials expanding to lung cancer | Lifileucel (Amtagvi) |
| Cancer Vaccines | Investigational / limited approved | Prostate cancer (sipuleucel-T remains) | Sipuleucel-T (Provenge) |
| Cytokine Therapies | Limited FDA-approved indications | Melanoma, renal cell carcinoma | IL-2 (aldesleukin) |
| PD-1 Inhibitors | Subset of ICI class | Melanoma, NSCLC, bladder, head & neck, more | Nivolumab (Opdivo), Pembrolizumab (Keytruda) |
| CTLA-4 Inhibitors | Subset of ICI class | Melanoma, renal cell carcinoma, colorectal (MSI-H) | Ipilimumab (Yervoy) |
| PD-L1 Inhibitors | Subset of ICI class | Bladder, lung, gastric cancers | Atezolizumab, Durvalumab, Cemiplimab |
| Q4 2025 New FDA Approvals (immunotherapy) | 3 new ICI indications + 1 new CAR-T indication | CSCC, gastric/GEJ, marginal zone lymphoma | Cemiplimab (Libtayo), Durvalumab (Imfinzi), Lisocabtagene maraleucel |
Source: FDA Oncology Approvals (AACR Q4 2025 Report, January 2026); NIH/NCI; Journal of Clinical Oncology, 2024; AACR Cancer Progress Report 2023
The FDA approval landscape for cancer immunotherapy in the US as of 2026 represents the cumulative result of over a decade of accelerating clinical development. The 11 FDA-approved immune checkpoint inhibitors, covering over 20 distinct cancer types, have effectively made ICI therapy a standard component of treatment protocols for melanoma, non-small cell lung cancer, bladder cancer, head and neck squamous cell carcinoma, gastric cancers, colorectal cancer (MSI-H), hepatocellular carcinoma, and many others. Pembrolizumab (Keytruda), with its 35 distinct approved indications, stands as the most broadly approved single cancer immunotherapy drug in US history — a testament to the versatility of PD-1 checkpoint blockade across tumor types. The Q4 2025 approvals further expanded the ICI reach, with cemiplimab (Libtayo) gaining a new post-surgical indication for high-risk cutaneous squamous cell carcinoma, and durvalumab (Imfinzi) earning its first approval for resectable gastric and gastroesophageal junction adenocarcinoma.
The CAR-T cell therapy segment represents a different but equally revolutionary approach: engineering a patient’s own T-cells outside the body, then infusing them back as living, cancer-targeting drugs. With 6 to 7 FDA-approved CAR-T therapies now available in the US — all targeting blood cancers — and up to 80% remission rates in certain lymphoma subtypes, CAR-T has transformed the prognosis for patients with relapsed or refractory hematologic malignancies who previously had no meaningful treatment options. The Q4 2025 approval of lisocabtagene maraleucel (Breyanzi) for marginal zone lymphoma further expanded this category, and the emerging field of TIL therapy — beginning with lifileucel in melanoma — is now being investigated for expansion into non-small cell lung cancer through trials like the IOV-LUN-202 study.
Cancer Immunotherapy Access & Racial Disparities in the US 2026
| Population Group / Factor | Statistic / Disparity | Context |
|---|---|---|
| Total US cancer survivors (Jan 1, 2025) | 18.6 million | Projected to exceed 22 million by 2035 |
| Black men — prostate cancer death rate vs. other groups | 2–4x higher mortality rate | Systemic access and screening barriers |
| Black patients — stage I rectal cancer surgery rate | 39% received surgery | vs. 64% of White patients — a 25-point gap |
| Black patients — stage I–II lung cancer surgery rate | 47% underwent surgery | vs. 52% of White counterparts |
| American Indian/Alaska Native (AIAN) — kidney, liver, stomach, cervical cancers | Double the mortality rates vs. national average | Highest overall cancer mortality rate in the US |
| Black women — uterine cancer death rate | Twice as high as White women | Linked to access disparities and later-stage diagnosis |
| Privately insured women — molecularly targeted therapy/immunotherapy receipt | Significantly more likely to receive therapy | vs. uninsured or Medicaid-insured women (breast cancer data) |
| Medicaid/uninsured patients | Less likely to receive novel therapies and enroll in clinical trials | Lung cancer continuum disparities (Bade et al., 2025) |
| Uninsured patients — stage I colorectal cancer 5-year survival | Lower survival than privately insured patients with stage II disease | Insurance status overrides stage advantage |
| HPV vaccination coverage range across US states | 38% (Mississippi) to 84% (Rhode Island) | Directly mirrors cervical cancer incidence rates by state |
| Cervical cancer incidence range across states | 6 per 100,000 (MA/NH) to 14–15 per 100,000 (MS/OK/AR/LA) | A two-fold variation across states |
| Cancer death rate geographic range | 122 per 100,000 (UT, HI) to 180 per 100,000 (KY) | A 48% gap driven largely by lung cancer and smoking rates |
Source: ACS Cancer Treatment and Survivorship Statistics 2025 (PMC/NIH, May 2025); ACS CAN Cancer Disparities Chartbook, April 2026; American Cancer Society Cancer Statistics 2026; AACR Cancer Progress Report 2025; Cancer Research Institute (CRI) 2026
The access and disparity data within US cancer immunotherapy in 2026 tells a story of two Americas: one where groundbreaking treatments are available and utilized, and another where structural barriers — insurance status, geography, race, and systemic inequities in care delivery — mean that the benefits of the immunotherapy revolution remain unevenly distributed. The 25-percentage-point surgical gap between Black and White patients with stage I rectal cancer is particularly striking, reflecting not a difference in biology, but a documented failure of equitable care delivery. Research from Bade et al. (2025) confirms that uninsured patients or those on Medicaid are less likely to receive novel therapies including immunotherapy and are less likely to enroll in clinical trials — the very mechanisms through which new treatments are validated and made available.
The geographic disparities are equally troubling. A 48% gap in cancer death rates between the lowest-mortality states (Utah, Hawaii at 122 per 100,000) and the highest (Kentucky at 180 per 100,000) reflects decades of differential exposure to risk factors, particularly tobacco use, but also reflects access to high-quality oncology care. The two-fold variation in cervical cancer incidence across states — despite cervical cancer being largely preventable through HPV vaccination — directly mirrors vaccination coverage rates that range from 38% in Mississippi to 84% in Rhode Island. This is a preventable tragedy. The American Cancer Society Cancer Action Network’s April 2026 Cancer Disparities Chartbook — released just days ago — underscores that closing these gaps requires not just scientific advancement, but targeted local, state, and federal policy action to expand access to prevention, screening, and treatment including immunotherapy.
NCI Budget & Cancer Immunotherapy Research Funding in the US 2026
| Funding Metric | FY2025 | FY2026 (Enacted) | Change |
|---|---|---|---|
| NCI Total Appropriation | ~$7.22 billion | $7.35 billion | +$128 million (+1.8%) |
| NCI as Share of NIH Budget | ~15.36% | ~15.36% | Maintained |
| NCI Cancer Treatment Research Allocation (FY2026 proposal) | — | ~$534 million | Dedicated treatment R&D |
| NCI Cancer Detection & Diagnosis Research | — | ~$457 million | Screening and early detection |
| NCI Cancer Biology Research | — | ~$479 million | Foundational science |
| NCI Cancer Prevention Research | — | ~$338 million | Risk reduction programs |
| Childhood Cancer Data Initiative (CCDI) — FY2026 | $50 million | $50 million | Maintained |
| Full course immunotherapy cost per US patient | — | >$150,000 per patient | High and rising |
| Cancer survivors in US (as of Jan 1, 2025) | — | 18.6 million | Projected 22M+ by 2035 |
| Cancer deaths averted in US since 1991 | — | ~4.8 million | Result of 34% death rate decline |
Source: NCI Budget & Appropriations Page (cancer.gov, March 2026); Consolidated Appropriations Act 2026 (H.R. 1748); NCI Congressional Justification FY2026; NBER March 2026; American Cancer Society Cancer Action Network (ACS CAN) 2026
The Consolidated Appropriations Act 2026 (H.R. 1748) ultimately provided NCI a total appropriation of $7.35 billion — an increase of $128 million compared to the FY2025 budget, a meaningful though modest expansion of the federal commitment to cancer immunotherapy research and oncology more broadly. This enacted figure stands in significant contrast to earlier proposed cuts that had alarmed the cancer research community: a presidential budget proposal had suggested cutting NCI’s budget by approximately 37%, which would have represented a $2.7 billion reduction and, in the words of the American Cancer Society Cancer Action Network, placed “future cancer cures in jeopardy.” That the final enacted appropriation increased rather than decreased reflects strong bipartisan recognition that the immunotherapy revolution — which has averted an estimated 4.8 million deaths since 1991 — was built on sustained federal research investment and cannot be sustained without it.
The $534 million allocated to cancer treatment research within NCI’s FY2026 budget directly supports the immunotherapy pipeline, including clinical trial networks like the SWOG Cancer Research Network, the Eastern Cooperative Oncology Group (ECOG-ACRIN), and the Children’s Oncology Group — all of which conduct practice-changing phase 2 and phase 3 trials across immunotherapy approaches. The persistent economic burden of immunotherapy access is also a critical concern: with a full course of checkpoint inhibitor or CAR-T therapy costing more than $150,000 per patient, financial hardship among cancer survivors is a well-documented and growing crisis, particularly among Medicare-age adults aged 65 and older who bear substantial out-of-pocket costs despite their coverage.
CAR-T Cell Therapy Statistics in the US 2026
| Metric | Data Point | Source/Context |
|---|---|---|
| Total FDA-approved CAR-T therapies (US) | 6–7 approved therapies | As of late 2024–2025 |
| CAR-T target antigens (primary) | CD19 and BCMA (B-cell maturation antigen) | All current US approvals target blood cancers |
| FDA-approved CAR-T indications | B-cell ALL, LBCL, Follicular Lymphoma, Mantle Cell Lymphoma, CLL, Multiple Myeloma | Hematologic malignancies only (solid tumor approvals pending) |
| CAR-T remission rate — certain lymphomas | Up to 80% remission | Real-world and clinical trial data |
| Large B-cell lymphoma — liso-cel remission duration | ~two-thirds of patients had remissions lasting 6–9+ months | Clinical trial data |
| Q4 2025 new CAR-T approval | Lisocabtagene maraleucel (Breyanzi) for marginal zone lymphoma | First approval for this indication |
| Combination TIL + ICI for GI cancers (NIH trial) | Significant improvement in metastatic GI cancer outcomes | NIH clinical trial, published April 2025 in Nature Medicine |
| TIL therapy — lifileucel | Approved for melanoma; expanding to NSCLC trials (IOV-LUN-202) | FDA-approved; lung trial ongoing 2025 |
| CAR-T therapy global availability | 10 therapies commercially available globally | US leads with 6–7 FDA-approved |
| Solid tumor CAR-T trials (2025 ASCO) | Phase I trials underway for HER2-positive breast cancer, mesothelioma, glioblastoma | Investigational; not yet FDA-approved |
Source: FDA Oncology Approvals; AACR Q4 2025 Approvals Report (January 2026); PMC/NIH — CAR-T Reviews 2025; NIH News Release (TIL therapy, June 2025); ASCO Annual Meeting 2025 (PMC peer-reviewed summary)
CAR-T cell therapy represents the leading edge of personalized cancer immunotherapy in the United States — a technology that transforms a patient’s own T-cells into precision-guided weapons against cancer. The 6 to 7 FDA-approved CAR-T therapies currently available in the US have collectively changed the treatment outlook for patients with relapsed or refractory blood cancers, a population that historically had very limited options after failing standard chemotherapy. The up to 80% remission rate seen in certain lymphoma subtypes with CAR-T therapy is arguably the most striking single efficacy statistic in modern oncology — a figure that would have been considered science fiction just fifteen years ago. The Q4 2025 approval of lisocabtagene maraleucel (Breyanzi) for the rare condition of marginal zone lymphoma further extended access to this transformative therapy.
The frontier for CAR-T in the US in 2026 lies in solid tumors — cancers like glioblastoma, mesothelioma, and HER2-positive breast cancer — where the tumor microenvironment presents significant challenges that have so far prevented the kind of results seen in blood cancers. The 2025 ASCO Annual Meeting featured Phase I CAR-T trials in these areas showing early promise: a HER2-targeted autologous CAR-T achieved a 75% disease control rate in HER2-positive breast cancer patients, and a novel anti-PD1-mesothelin CAR-T achieved 100% overall response rate at a specific dose level in advanced mesothelioma patients. Meanwhile, tumor-infiltrating lymphocyte (TIL) therapy — an adoptive cell therapy in which immune cells extracted directly from a patient’s tumor are expanded and reinfused — is being actively investigated for non-small cell lung cancer through the IOV-LUN-202 trial, following the landmark NIH study published in Nature Medicine in April 2025 that demonstrated a new form of TIL therapy dramatically improved outcomes in metastatic gastrointestinal cancers.
Cancer Immunotherapy Response Rates by Cancer Type in the US 2026
| Cancer Type | Immunotherapy Approach | Overall Response Rate (ORR) | Key Outcome Data |
|---|---|---|---|
| Advanced Melanoma | Nivolumab + Ipilimumab (dual ICI) | ~58% | 52% 5-year OS; chemo median OS was ~6.2 months |
| NSCLC — PD-L1 ≥50% | Pembrolizumab monotherapy | ~45% (KEYNOTE-024) | 5-year OS: 23.2% vs. 15.5% (chemo) |
| NSCLC — any PD-L1 | Pembrolizumab (KEYNOTE-042) | Improved OS over chemo | Approved for PD-L1 TPS ≥1%; ~8 months extended OS |
| Urothelial/Bladder Cancer | Atezolizumab + chemo (IMvigor130) | — | Median OS: 16.0 months vs. 13.4 months (chemo alone) |
| Metastatic GI Cancers | TIL therapy (NIH combination, 2025) | Dramatic improvement | Published April 2025, Nature Medicine; major ORR gains |
| Head & Neck Squamous Cell Carcinoma | Pembrolizumab (neoadjuvant + adjuvant, 2025) | Significant reduction in disease progression/death | FDA approved June 2025 |
| Gastric/GEJ Adenocarcinoma | Durvalumab + chemo (neoadjuvant + adjuvant) | — | First approval for this cancer type (Q4 2025) |
| Cutaneous Squamous Cell Carcinoma (CSCC) | Cemiplimab (post-surgical, high-risk) | — | Q4 2025 FDA approval; reduces recurrence risk |
| Relapsed/Refractory Large B-Cell Lymphoma | CAR-T (liso-cel) | ~2/3 had durable remissions (6–9+ months) | FDA-approved; transformative in refractory disease |
| Marginal Zone Lymphoma | Lisocabtagene maraleucel (Breyanzi) | — | Q4 2025 FDA approval; first approval for this lymphoma type |
Source: AACR Q4 2025 Approvals Blog (January 2026); OncoDaily Immunotherapy Success Rates 2025; NIH News Release (TIL therapy, June 2025); MSK Cancer Center FDA Approvals 2025 Report; PMC — Advancing Cancer Treatment: ICI Review (April 2025)
The response rate data for cancer immunotherapy across cancer types in the US in 2026 underscores both the extraordinary potency of these treatments for specific malignancies and the wide variability in response depending on tumor biology, PD-L1 expression, tumor mutational burden (TMB), and other biomarkers. The 58% overall response rate for the combination of nivolumab and ipilimumab in advanced melanoma — paired with a 52% five-year overall survival — stands as the benchmark achievement of the checkpoint inhibitor era, demonstrating that durable, potentially curative responses are achievable in what was once considered a near-universally fatal diagnosis. In non-small cell lung cancer, the picture is more nuanced: pembrolizumab monotherapy delivers its strongest benefit in patients with PD-L1 expression ≥50%, where five-year survival of 23.2% compares favorably with the 15.5% seen with chemotherapy — a relative improvement that, while not as dramatic as melanoma, is clinically significant and represents hundreds of thousands of additional life-years for American patients.
The newest Q4 2025 FDA approvals — including durvalumab for gastric and GEJ adenocarcinoma, cemiplimab for high-risk post-surgical cutaneous squamous cell carcinoma, and CAR-T for marginal zone lymphoma — continue to expand the reach of immunotherapy into cancer types that had limited options just months ago. The NIH TIL therapy study published in Nature Medicine in April 2025, demonstrating dramatic improvement in metastatic gastrointestinal cancer outcomes through a novel combination approach, represents one of the most clinically meaningful recent advances in cancer immunotherapy and is already generating follow-on trial designs. What ties all of these developments together is the recognition that the immune system, properly activated and directed, is capable of achieving responses that no chemical agent alone can replicate — and that the work of expanding, refining, and ensuring equitable access to these therapies will define American oncology for the next generation.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.